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Abstracts
Gregory L. Moneta, MD, Section EditorA Randomized Trial of Rosuvastatin in the Prevention of Venous
Thromboembolism
GlynnRJ,Danielson E, Fonseca FAH, et al. NEngl JMed 2009;360:1851-61.
Conclusion: In healthy persons, rosuvastatin reduces the occurrence of
symptomatic venous thromboembolism.
Summary: Some observational studies have suggested a decreased risk
of venous thromboembolism (VTE) in patients treated with statins (Ann
Intern Med 2000;132:689-96, and Arch Intern Med 2001;161:1405-10).
Other studies, however, have shown no association between the use of
statins and venous thrombosis (Br J Clin Pharm 2008;67:99-109). The
current study is a subanalysis of the Justification of the Use of Statins in
Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER).
JUPITER examined whether or not rosuvastatin, 20 mg daily, compared
with placebo, would reduce the rates of first major cardiovascular events.
The occurrence of VTE was a protocol-specified secondary end point of
JUPITER.
The study randomly assigned 17,802 apparently healthy men and
women to receive rosuvastatin, 20 mg daily, or placebo. Patients were
monitored for first occurrence of pulmonary embolism (PE) or deep venous
thrombosis (DVT). Data were analyzed on an intention to treat basis.
Median follow-up was 1.9 years (maximum, 5.0 years). Symptomatic VTE
occurred in 94 participants: 60 in the placebo group and 34 in the rosuva-
statin group. Rates of VTE were 0.18/100 person-years in the rosuvastatin
group (hazard ratio [HR], 0.57; 95% confidence interval (CI), 0.37-0.86; P
 .007) and 0.32/100 person-years in the placebo group. For unprovoked
VTE, that is, VTE occurring in the absence of known malignant conditions,
surgery, trauma, or hospitalization, rates were 0.10/100 person-years in the
rosuvastatin group and 0.17/100 person-years in the placebo group (HR,
0.61, 95% CI, 0.35-1.09; P .09). Rates for provoked VTEwere 0.08/100
person-years in the rosuvastatin group and 0.16/100 person-years in the
placebo group (HR, 0.52; 95% CI, 0.28-0.96; P .03). Rates of PE did not
differ between the rosuvastatin group and placebo groups. Rates of DVT
were 0.09/100 patient-years in the rosuvastatin group and 0.20/100 pa-
tient-years in the placebo group (HR, 0.45; 95% CI, 0.25-2.79; P  .004).
There were no differences between treatment groups in the rates of bleeding
episodes.
Comment:Venous and arterial thromboses carry some risk factors that
are shared. The nature and extent of these shared pathways and whether
demonstrated efficacy for prevention of one condition can translate to the
other is controversial. This study suggests another potentially important
pleiotropic effect of statin medications. This study was prospective and
double-blind, and prespecified VTE as an end point, and therefore has
considerable strength. However, the study only occurred in patients who
were thought to be healthy, there is relatively limited follow-up, and it does
not allow for evaluation of the relationship between the dose of statin and
risk of VTE. Future data, particularly on the ability of statin medications to
decrease VTE in higher-risk patients will be interesting.
Associations of Borderline and Low Normal Ankle-Brachial Index
Values With Functional Decline at 5-Year Follow-Up. The WALCS
(Walking and Leg Circulation Study)
McDermott MM, Guralnik JM, Tian L, et al. J Am Coll Cardiol 2009;53:
1056-62.
Conclusion: A “low-normal” ankle-brachial index (ABI) has an in-
creased incidence of late mobility loss compared with a normal ankle-
brachial index (ABI).
Summary: An estimated 8 million persons in the United States have
peripheral arterial disease (PAD) of the lower extremities. PAD is defined as
an ABI 0.9. These patients have increased rates of functional decline and
greater functional impairment than those without PAD. In this study, the
authors sought to ascertain the possible association between functional
decline and the presence of borderline or low-normal ABI values. They
hypothesized that patients with borderline or low-normal baseline ABI
values would have slower rates of functional decline than PAD patients and
that functional decline would be greater than in persons with a normal ABI.
Participants in this study were part of theWalking and Leg Circulation Study
(WALCS) study to identify predictors of functional decline in persons with
and without PAD. Of the 666 study participants, 412 had PAD. Participants
were categorized as having severe PAD (ABI 0.5), moderate (ABI 0.5-
0.69), mild (ABI 0.7-0.89), borderline to low-normal (ABI 0.9-1.09), or
normal without PAD (ABI 1.10-1.30). Mobility loss was defined as loss of
ability to walk one-quarter mile or walk up and down one flight of stairs
without assistance in individuals who did not have baseline mobility impair-ment. Participants unable to walk for 6 minutes were defined as stopping
during a 6-minute walk test during a follow-up examination when they were
able to complete the 6-minute walk test on their initial study. Outcomes
were assessed annually for 5 years, and results were adjusted for age, race,
comorbidities, gender, and other confounders.
Hazard ratios for mobility loss according to ABI category were severe
PAD, 4.16 (95% confidence interval [CI], 1.58-10.92); moderate PAD,
3.82 (95% CI, 1.66-8.81); mild PAD, 3.22 (95% CI, 1.43-7.21); borderline
PAD, 3.07 (95% CI, 1.21-7.84); and low-normal PAD, 2.61 (95% CI,
1.08-6.32; P trend  .0018). Associations for becoming unable to walk for
6 minutes continuously were similar (P trend .0001).
Comment: ABI values 0.9 are both specific and sensitive for a
diagnosis of PAD. The findings here suggest that patients with low-normal
or borderline ABI values have higher rates of functional decline than patients
with truly normal ABIs (1.1 to 1.3). These results may reflect a higher rate of
progression of lower extremity atherosclerosis among patients with low-normal
and borderline ABI values. Alternatively, low-normal and borderline ABI values
may be markers for atherosclerosis elsewhere or other comorbidities that can
influence mobility and performance on the 6-minute walk test. What is clear is
that functional impairment is associated with even very mild PAD.
Diagnostics of “non-acute” vascular prosthesis infection using 18F-
FDG PET/CT: our experience with 96 prostheses
Spacek M, Belohlavek O, Votrubova J, et al. Euro J Nuc Med Mol Imaging
2009;36:850-8.
Conclusion: Positron emission tomography (PET)/computed to-
mography (CT) imaging is an excellent diagnostic modality for suspected
vascular prosthetic graft infection (VPGI).
Summary: The use of hybrid imaging technology is increasing; in
particular, the combination of PET and CT using 18F-fluorodeoxyglucose
(18F-FDG) has become a well-accepted tool for diagnosis of cancer. Hybrid
technologies provide a combination of high spatial resolution morphologic
CT data with functional PET data in one image. Tissues with highmetabolic
activity are characterized by cumulative FDG uptake. 18F-FDG PET also
has a high sensitivity for diagnosis of infection and inflammation. The
purpose of this study was to test the accuracy of FDG PET/CT in the
diagnosis of VPGI. The authors sought to evaluate this technology in a set of
patients with possible low-grade VPGIs and nonacute presentations. They
performed PET/CT prospectively in 76 consecutive patients (52 men, 24
women) with 96 prosthetic grafts with suspected VPGI. Studies were
performed between May 2004 and May 2007. Patients were recruited from
a large tertiary vascular surgery referral center in Czechoslovakia. The
presence and intensity of focal and diffuse FDG uptake was analyzed from
the PET/CT scans. Also analyzed was the presence of an anastomotic
aneurysm, presence of an irregular boundary of infiltration, combinations of
these, and an uptake ratio between the graft and blood background.
PET/CT findings were then compared with operative and histopathologic
findings or clinical follow-up 6 months.
Of the assessed parameters, only an irregular graft boundary and focal
FDG uptake were significant predictors of VPGI. If focal intense FDG
uptake and an irregular boundary of the lesion were both present on the CT
scan, this correlated with a 97% probability of a VPGI. Smooth lesion bound-
aries and no focal FDG uptake predicted a probably of VPGI of 5%. When
there was inhomogeneous focal FDG uptake (18 of the 96 patients), an
irregular boundary on the CT scan aided decision making with a probability of
28% for a VPGI if the boundary was smooth vs a probability of 77% for VPGI if
the boundary was irregular. In this study, 57.3% of the prosthetic grafts evalu-
ated (55 of 96) eventually had a clinical diagnosis of VPGI. The presence of
intense focal FDG uptake was specific for VPGI in 92.7% of prostheses and had
a very high positive predictive value of 93.5% for predicting VPGI.
Comment: Low-grade infection of a prosthetic graft can be difficult to
diagnose. The authors’ technique of combining FDG PET/CT provides
anatomic, functional, andmetabolic data in a single session. CT scanning has
only about 55% sensitivity with respect to detecting low-grade VPGI. The
hybrid imaging technique presented here appears to offer a substantial
improvement over CT scanning alone in the detection of low-grade VPGI.
Improved Long-Term Survival After Abdominal Aortic Aneurysm
Repair
Mani K, Björck M, Lundkvist J, et al. Circulation 2009;120:201-11.Conclusion: Despite a change in case-mix toward older patients with
increased comorbidity, long-term survival after repair of an intact abdominal
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October 2009960 Abstractsaortic aneurysm (AAA) has improved over time and has remained stable after
ruptured AAA repair.
Summary: This article is an analysis of data from the Swedish Vascular
Registry. During the time of this analysis, the incidence of intact AAA repair
in Sweden increased significantly, whereas the incidence of ruptured AAA
repair did not change. Overall, however, it appears mortality may be decreas-
ing for both intact and ruptured AAA repair (Br J Surg 2008;95:564-70).
Improved short-term survival combined with increasing age of patients
treated for AAA could potentially result in a reduction of long-term survival.
The authors therefore analyzed long-term crude and relative survival after
AAA repair in Sweden during an 18-year period from 1987 to 2005.
During the study period, 8663 primary intact and 4171 ruptured AAA
repairs were recorded in the Swedish Vascular Registry. Mortality was
determined from the national population registry. Crude survival was ana-
lyzed. Also analyzed was relative survival, being the survival rate of patients
compared with that of the general population adjusted for age, sex, and
calendar year, excluding 90-day mortality. When AAA repairs from 1987 to
1999 were compared with those from 2000 to 2005, patient age increased
from 71.4 to 72.2 years (P .001), the percent of patients with comorbidi-
ties increased from 65.5% to 68.5% (P  .001), and use of endovascular
repair increased from 1.6% to 17.0% (P  .001). Crude 5-year survival after
intact AAA repair was 69.0% (99% confidence interval [CI], 67.7%-70.4%).
Relative 5-year survival, excluding 90-day mortality, was 90.3% (99% CI,
88.6%-92.0%). For those who underwent operations from 2000 to 2005,
relative survival was better compared with those who underwent operations
from 1987 to 1999 (difference 4.7%; 99% CI, 1.3%-8.1%). Relative survival
was also better formen vs women (difference, 4.6%; 99%CI, 0.4%-8.8%). No
difference was observed between open and endovascular repair (6%, 99% CI,
1.5% to 13.4%). After ruptured AAA repair, the crude 5-year survival was
41.7% (99% CI, 39.6%-43.7%) and relative survival was 87.1% (99% CI,
83.9%-90.3%). No differences in relative 5-year survival were observed
between time period, sex, or age groups.
Comment: The data indicate AAA repair is an effective operation for
prolonging survival, although certainly repair of an AAA does not appear to
return the patients to a normal expected survival compared with age- and
sex-matched controls without an AAA. Further improvements in long-term
survival after AAA repair will likely be primarily based on better medical
management of patients with vascular disease. The challenge will be to do
this in a cohort of patients of increasing age and increasing comorbidities.
Residual Thrombosis on Ultrasonography to Guide the Duration of
Anticoagulation in Patients With Deep Venous Thrombosis: A Ran-
domized Trial
Prandoni P, Prins MH, Lensing AWA, and the AESOPUS Investigators.
Ann Intern Med 2009;150:577-85.
Conclusion: Rates of recurrent venous thromboembolism (VTE) in
adults with proximal deep venous thrombosis (DVT) can be reduced by
tailoring the duration of anticoagulation on the basis of ultrasound findings.
Summary: Patients with DVT are known to have an increased risk for
recurrent VTE after anticoagulation (JAMA 2005;294:706-15). Anticoag-
ulation is generally prescribed for 3 months for patients with reversible risk
factors and for a minimum of 6 months for those patients with permanent
risk factors or venous thrombosis (Chest 2008;133:454-5s). An association
has been suggested between residual thrombosis present by ultrasound
imaging at the time warfarin therapy is discontinued and an increased risk of
subsequent recurrent VTE (Ann Intern Med 2002;137:955-60). The au-
thors performed a randomized trial to evaluate the efficacy of tailoring the
duration of anticoagulation based on recanalization or persistence of residual
venous thrombosis as determined by ultrasound imaging. Patients with the
first episode of proximal DVT who completed 3 months of anticoagulation
were assigned to receive fixed-duration anticoagulation or flexible ultra-
sound-guided anticoagulation. This was a randomized, multicenter, open-
label trial with independent and blinded assessments of study outcomes.
Patients were recruited between January 1999 and July 2003, and the study
ended when the last recruited patient had 3 years of follow-up. The study
was conducted at nine centers in Italy. In patients assigned to the fixed-
duration of anticoagulation, those with unprovoked DVT received 3 addi-
tional months of treatment for a total of 6 months, and anticoagulation was
discontinued after 3 months in those with secondary DVT. Patients assigned
to a flexible-duration of anticoagulation underwent ultrasound imaging
after 3 months of anticoagulation. If the veins had recanalized, anticoagu-
lation was discontinued. If the veins had not recanalized, patients were
invited to undergo further ultrasound imaging after 3 and 9 months if they
had a secondary DVT and to undergo further examinations after 3, 6, 9, 15,
and 20 months if they had had an unprovoked DVT. Anticoagulation was
discontinued when the veins had recanalized. Patients were monitored for
symptomatic recurrent VTE and major bleeding episodes.
Of 538 consecutive patients who underwent a 3-month period of
anticoagulation, 530 completed the trial. Overall, recurrent VTE developed
in 46 of 268 patients (17.2%) allocated to fixed-duration anticoagulation
and 32 of the 270 (11.9%) allocated to flexible-duration anticoagulation
(hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.39-0.99). Ifpatients had unprovoked DVT, the adjusted HR was 0.61 (95% CI, 0.36-
1.02). In those with secondary DVT, the HR ratio was 0.81 (95% CI,
0.32-2.06). Major bleeding occurred in 0.7% of patients in the fixed-
duration group and in 1.5% in the flexible-duration group (P  .67).
Comment: Tailoring the duration of oral anticoagulant therapy based
on follow-up ultrasound studies reduced the risk of recurrent VTE by 35%
compared with a fixed-duration administration of warfarin therapy. The data
also suggest the greatest benefit of flexible-duration warfarin therapy is in
those with unprovokedDVT. Themajor problem in extrapolating these data
to clinical practice is the authors’ criteria for determining recanalization of a
thrombosed vein. Ultrasound criteria for quantifying residual venous throm-
bosis are not widely used. Their criteria for a recanalized vein were that a vein
was 2 mm in diameter with probe compression or 3 mm in diameter on
two consecutive examinations. These criteria differ substantially from other
criteria used to determine the presence of residual thrombosis after VTE (J
Thromb Haemost 2006;4:1919-24). Additional studies will be needed to
determine if the authors’ approach and, in particular, their method of
determining recanalization of a thrombosed vein is medically sound, safe,
and cost-effective in routine clinical practice.
Similarity of the Impact of Type 1 and Type 2 Diabetes on Cardiovas-
cular Mortality in Middle-Aged Subjects
Juutilainen A, Lehto S, Rönnemaa T, et al. Diabetes Care 2008;31:714-9.
Conclusion: Type 1 and type 2 diabetes have a similar effect on
cardiovascular disease mortality. Increased hyperglycemia affects cardiovas-
cular disease mortality more profoundly in type 1 than type 2 diabetic
individuals.
Summary: Type 1 and type 2 diabetes are characterized by high blood
glucose levels. Type 1 diabetes, however, is primarily due to destruction of
pancreatic -cells and results in insulin deficiency. Type 2 diabetes is char-
acterized by insulin resistance and impaired insulin secretion and accounts
for 80% of cases of diabetes mellitus. Both diseases share some common
predisposing factors such as obesity. An increased concentration of blood
glucose appears to be a primary risk factor for microvascular complications in
both type 1 and type 2 diabetes. Hyperglycemia is considered a major risk
factor for macrovascular complications in type 1 diabetes; however, the role
of hyperglycemia as a risk factor for cardiovascular disease in type 2 diabetes
is not uniformly accepted. The authors sought to investigate the effect of
both types of diabetes on the risk of cardiovascular disease and the effect of
glycemia on death in type 2 and type 1 diabetes.
Only patients with diabetes who were aged 30 years when the
diagnosis was made were included in the study. The study took place in
Finland, and the selection of the cohort was based on a drug reimbursement
registry maintained by the Social Insurance Institution of Finland. The study
consisted of 173 participants with type 1 diabetes, 834 with type 2 diabetes,
and 1294 nondiabetic participants. All participants were age 45 to 64 years
at baseline and were thought to be free of cardiovascular disease.
Follow-up lasted 18 years. There were 86 deaths in the participants
with type 1 diabetes, 567 deaths in patients with type 2 diabetes, and 252
deaths in the nondiabetic participants. The hazard ratio (HR) for cardiovas-
cular mortality in men with type 1 diabetes vs those patients with no diabetes
was 3.6 (95% confidence interval [CI], 2.2-5.7). The HR for cardiovascular
disease mortality in type 1 diabetic women vs those with no diabetes was
13.3 (95% CI, 6.9-22.5) and in patients with type 2 diabetes vs no diabetics,
the HRs were 3.3 (95% CI, 2.5-4.5) in men and 10.1 (95% CI, 6.7-17.4) in
women. An increment of 1 unit (%) of hemoglobin A1C increased cardio-
vascular disease mortality by 52.5% in type 1 diabetic participants and by
7.5% in type 2 diabetic participants.
Comment:We are filling in the details regarding the cardiovascular risk of
patients with diabetes. Whereas we all recognize an increased risk for cardiovas-
cular disease and death in the diabetic patient, studies such as this indicate that
not all diabetic patients are the same. Apparently, cardiovascular risk is similar in
type 1 and type 2 diabetic patients, but control of glucose levels in lowering the
risk of cardiovascular disease may be more important in the type 1 diabetic
patient than in those with type 2 diabetes, especially for women.
The Effects of Increasing Obesity on Outcomes of Vascular Surgery
Khandanpour N, Armon MP, Foxall R. Ann Vas Surg 2009;23:310-6.
Conclusion: Vascular procedures on morbidly obese patients require
longer operating times and have higher rates of infection, but this does not
translate into worse final outcomes.
Summary:Worldwide, there are at least 300million obese patients and
1 billion adults who are overweight. Obesity contributes to increased health
care cost and increased deaths; however, the effect of obesity on periopera-
tive morbidity and mortality, especially in vascular surgical patients, is not
well established. The authors sought to determine whether a body mass
index (BMI) 35 kg/m2 (morbid obesity) affects the morbidity and mor-
tality of patients undergoing vascular surgery. The study took place in the
United Kingdom, where men reportedly are in the highest quintile of
obesity in Europe and women are in the second highest. The data were
